3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
3
Terminated
2
Withdrawn
1
Unknown
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Multiple Myeloma
24
Lymphoma
16
Neoplasms, Plasma Cell
12
Lymphoma, Non-Hodgkin
11
Lymphoma, Large B-Cell, Diffuse
8
Neuroblastoma
7
Lymphoma, Mantle-Cell
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Hodgkin Disease
6
Myelodysplastic Syndromes
5
Lymphoma, Large-Cell, Immunoblastic
5
Leukemia
5
Burkitt Lymphoma
5
Lymphoma, Follicular
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Recurrence
3
Lymphoma, B-Cell, Marginal Zone
3
Leukemia, Myeloid, Chronic-Phase
3
Leukemia, Myeloid, Acute
3
Sarcoma
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroectodermal Tumors, Primitive
2
Medulloblastoma
2
Lymphoma, T-Cell
2
Lymphoma, Large-Cell, Anaplastic
2
Leukemia, Myeloid, Accelerated Phase
2
Leukemia, Biphenotypic, Acute
2
Dendritic Cell Sarcoma, Interdigitating
2
Brain Neoplasms
2
Interventions
pegaspargase
14
Etoposide
11
Dexamethasone
11
Gemcitabine
10
spartalizumab
6
Oxaliplatin
4
sintilimab
3
Radiotherapy
3
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
3
Methotrexate
3
Asparaginase
3
tislelizumab
2
camrelizumab
2
Lenalidomide
2
Drug Therapy
2
Cyclophosphamide
2
Cisplatin
2
Busulfan
2
Azacitidine
2
toripalimab
1
tofacitinib
1
ruxolitinib
1
romidepsin
1
pembrolizumab
1
fludarabine phosphate
1
avelumab
1
apatinib
1
Thalidomide
1
Sensitivity and Specificity
1
Psychiatric Rehabilitation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Lymphoma, Extranodal NK-T-Cell
×
Melphalan
×
Clear all
NCT02544425
2020-10-22
VIDL+ASCT
Samsung Medical Center
Phase 2
Unknown
27 enrolled